Importantly, treatment with either anti-CD47 or anti-SIRPα antibodies ameliorated liver inflammation and fibrosis by enhancing the clearance of necroptotic hepatocytes, suggesting that therapeutic blockade of the CD47-SIRPα axis acts as a strategy to dampen MASLD progression [136]. Here, CD47 is linked to metabolic dysfunction-associated steatotic liver disease.